CAS 1997361-87-1

Lixisenatide acetate

Description:

Lixisenatide acetate is a synthetic peptide and a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used in the management of type 2 diabetes mellitus. It is characterized by its ability to enhance insulin secretion in response to elevated blood glucose levels, thereby aiding in glycemic control. The substance is derived from the exendin-4 peptide, which is found in the saliva of the Gila monster, and has been modified to improve its pharmacokinetic properties. Lixisenatide acetate is typically administered via subcutaneous injection and has a relatively short half-life, necessitating once-daily dosing. Its mechanism of action includes slowing gastric emptying and promoting satiety, which can contribute to weight loss in patients. The acetate form serves to stabilize the peptide and enhance its solubility. As with other GLP-1 receptor agonists, potential side effects may include gastrointestinal disturbances, such as nausea and vomiting, as well as a risk of pancreatitis. Overall, lixisenatide acetate represents a valuable therapeutic option in the comprehensive management of diabetes.

Synonyms:

• Lixisenatide acetate (320367-13-3 free base)
• Lixisenatide,inhibit,Glucagon Receptor,Lixisenatide acetate (320367 13 3 free base),Inhibitor,Lixisenatide acetate (320367133 free base),GCGR

Lixisenatide acetate (320367-13-3 free base)

CAS: 1997361-87-1

Lixisenatide acetate is a receptor agonist similar to glucagon-like peptide-1 (glp-1) for the treatment of type 2 diabetes mellitus (T2DM).

Formula: C₂₁₅H₃₄₇N₆₁O₆₅S·6C₂H₄O₂

Purity: 98% - 99.9%

Color and Shape: Solid

Molecular weight: 5218.88

Ref: TM-TP1469

Lixisenatide acetate

CAS: 1997361-87-1

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is used to treat type 2 diabetes. Lixisenatide has been shown to be safe and effective in patients with renal impairment, hepatic impairment, or congestive heart failure. The pharmacokinetics of lixisenatide have been studied in healthy subjects and patients with chronic renal failure receiving dialysis. Lixisenatide has been shown to have a linear pharmacokinetic profile in both populations and has not been found to accumulate in the plasma after repeated doses. Lixisenatide does not bind tightly to human serum albumin, which may make it more suitable for use in patients with atherosclerotic cardiovascular disease who exhibit hyperlipidemia because it will be less likely to affect lipid profiles.

Formula: C₂₁₅H₃₄₇N₆₁O₆₅S•(C₂H₄O₂)x

Purity: Min. 95%

Color and Shape: Powder

Ref: 3D-FL76758

Lixisenatide Acetate

Controlled Product

CAS: 1997361-87-1

Formula: C₂₁₅H₃₄₇N₆₁O₆₅S·C₂H₄O₂

Color and Shape: Neat

Molecular weight: 4858.48 + x(60.05)

Ref: TR-L320360